30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Cyclerion Therapeutics Inc (CYCN)

Track

Stock chart
Ticker: CYCN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Slate Path Capital LP
1 sale — total 555,108 USD
Sale 21 Nov 2024
Value US$2,354,993.21 | Price 344.73 | Shares 22,322
Sale 9 Aug 2023
Value US$1,790,978.07 | Price 381.29 | Shares 20,795
Buy 3 Jun 2021
Value US$2,699,997.60 | Price 3.28 | Shares 823,170
Buy 3 Jun 2021
Value US$10,364.64 | Price 3.12 | Shares 3,322
Buy 3 Jun 2021
Value US$289,632.72 | Price 3.12 | Shares 92,831
Buy 6 May 2021
Value US$733,860.00 | Price 2.43 | Shares 302,000
Planned sale 25 Feb 2021
Value US$7,296.00 | Price 4.00 | Shares 1,824
Planned sale 25 Feb 2021
Value US$10,521.63 | Price 3.99 | Shares 2,637
Sale 28 Dec 2020
Value US$60,522.07 | Price 3.01 | Shares 20,107
Planned buy 9 Nov 2020
Value US$316,250.00 | Price 2.53 | Shares 125,000
Planned sale 6 Nov 2020
Value US$9,644.04 | Price 2.52 | Shares 3,827
Planned sale 21 Feb 2020
Value US$18,222.08 | Price 5.12 | Shares 3,559
Sale 30 Dec 2019
Value US$62,000.00 | Price 2.48 | Shares 25,000
Sale 27 Dec 2019
Value US$63,750.00 | Price 2.55 | Shares 25,000
Buy 15 Nov 2019
Value US$227,500.00 | Price 1.82 | Shares 125,000
Planned sale 8 Nov 2019
Value US$8,040.10 | Price 2.05 | Shares 3,922
Buy 8 Apr 2019
Value US$346,160.00 | Price 16.00 | Shares 21,635
Buy 8 Apr 2019
Value US$9,671,712.00 | Price 16.00 | Shares 604,482
Buy 8 Apr 2019
Value US$346,160.00 | Price 16.00 | Shares 21,635
Buy 8 Apr 2019
Value US$9,671,712.00 | Price 16.00 | Shares 604,482
Buy 2 Apr 2019
Value US$4,000,284.67 | Price 14.81 | Shares 270,107
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-11-25 2024-11-21 S Sale
0.5
Slate Path Capital LP
Large shareholder
22,322 +18.5%
344.73
US$2,354,993 		22,322 +18.5% 344.73 US$2,354,993
2023-08-11 2023-08-09 S Sale
1.4
MCGUIRE TERRANCE
Non-Executive Director
20,795 +19.7%
381.29
US$1,790,978 		20,795 +19.7% 381.29 US$1,790,978
2021-06-07 2021-06-03 B Purchase
2.6
Hecht Peter M

Chief Executive Officer

Executive Director
33,750 -10.0%
283.33
US$3,559,349 		33,750 -10.0% 283.33 US$3,559,349
2021-06-07 2021-06-03 B Purchase
1.4
MCGUIRE TERRANCE
Non-Executive Director
3,322 +15.4%
3.12
US$10,365 		3,322 +15.4% 3.12 US$10,365
2021-06-07 2021-06-03 B Purchase
1.4
MCGUIRE TERRANCE
Non-Executive Director
92,831 +15.4%
3.12
US$289,633 		92,831 +15.4% 3.12 US$289,633
2021-05-10 2021-05-06 B Purchase
2.6
Hecht Peter M

Chief Executive Officer

Executive Director
302,000 +32.7%
2.43
US$733,860 		302,000 +32.7% 2.43 US$733,860
2021-03-01 2021-02-25 PlS Planned sale
Gjino Anjeza

Chief Financial Officer

Officer
1,824 -5.5%
4.00
US$7,296 		1,824 -5.5% 4.00 US$7,296
2021-03-01 2021-02-25 PlS Planned sale
Wright Christopher I

Chief Medical Officer

Officer
2,637 -5.8%
3.99
US$10,522 		2,637 -5.8% 3.99 US$10,522
2020-12-30 2020-12-28 S Sale
2.0
Currie Mark G

President and CSO

Officer
20,107 -7.4%
3.01
US$60,522 		20,107 -7.4% 3.01 US$60,522
2020-11-12 2020-11-09 PP Planned purchase
4.0
Busch Andreas

Chief Innovation Officer

Officer
125,000 +96.4%
2.53
US$316,250 		125,000 +96.4% 2.53 US$316,250
2020-11-10 2020-11-06 PlS Planned sale
0.5
Huyett William

Chief Financial Officer

Officer
3,827 -5.4%
2.52
US$9,644 		3,827 -5.4% 2.52 US$9,644
2020-02-25 2020-02-21 PlS Planned sale
0.5
Huyett William

Chief Financial Officer

Officer
3,559 -4.7%
5.12
US$18,222 		3,559 -4.7% 5.12 US$18,222
2019-12-31 2019-12-30 S Sale
2.0
Currie Mark G

President

Officer
25,000 -8.4%
2.48
US$62,000 		25,000 -8.4% 2.48 US$62,000
2019-12-31 2019-12-27 S Sale Currie Mark G

President

Officer
25,000 -7.8%
2.55
US$63,750 		25,000 -7.8% 2.55 US$63,750
2019-11-19 2019-11-15 B Purchase Busch Andreas

Chief Innovation Officer

Officer
125,000 +inf%
1.82
US$227,500 		125,000 +inf% 1.82 US$227,500
2019-11-12 2019-11-08 PlS Planned sale Huyett William

Chief Financial Officer

Officer
3,922 -5.0%
2.05
US$8,040 		3,922 -5.0% 2.05 US$8,040
2019-04-10 2019-04-08 B Purchase
1.4
MCGUIRE TERRANCE
21,635 +inf%
16.00
US$346,160 		21,635 +inf% 16.00 US$346,160
2019-04-10 2019-04-08 B Purchase
1.4
MCGUIRE TERRANCE
604,482 +inf%
16.00
US$9,671,712 		604,482 +inf% 16.00 US$9,671,712
2019-04-10 2019-04-08 B Purchase
2.6
SCHULMAN AMY W
21,635 +inf%
16.00
US$346,160 		21,635 +inf% 16.00 US$346,160
2019-04-10 2019-04-08 B Purchase
2.6
SCHULMAN AMY W
604,482 +inf%
16.00
US$9,671,712 		604,482 +inf% 16.00 US$9,671,712
2019-04-03 2019-04-02 B Purchase
2.0
Currie Mark G

President
270,107 +523.0%
14.81
US$4,000,285 		270,107 +523.0% 14.81 US$4,000,285
Explore more

More insider trading research around Cyclerion Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America